These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 32424275)

  • 1. Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance.
    Bi M; Zhang Z; Jiang YZ; Xue P; Wang H; Lai Z; Fu X; De Angelis C; Gong Y; Gao Z; Ruan J; Jin VX; Marangoni E; Montaudon E; Glass CK; Li W; Huang TH; Shao ZM; Schiff R; Chen L; Liu Z
    Nat Cell Biol; 2020 Jun; 22(6):701-715. PubMed ID: 32424275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.
    Cottu P; Bièche I; Assayag F; El Botty R; Chateau-Joubert S; Thuleau A; Bagarre T; Albaud B; Rapinat A; Gentien D; de la Grange P; Sibut V; Vacher S; Hatem R; Servely JL; Fontaine JJ; Decaudin D; Pierga JY; Roman-Roman S; Marangoni E
    Clin Cancer Res; 2014 Aug; 20(16):4314-25. PubMed ID: 24947930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
    Wu Y; Zhang Z; Cenciarini ME; Proietti CJ; Amasino M; Hong T; Yang M; Liao Y; Chiang HC; Kaklamani VG; Jeselsohn R; Vadlamudi RK; Huang TH; Li R; De Angelis C; Fu X; Elizalde PV; Schiff R; Brown M; Xu K
    Cancer Res; 2018 Feb; 78(3):671-684. PubMed ID: 29212856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance.
    Yu-Rice Y; Jin Y; Han B; Qu Y; Johnson J; Watanabe T; Cheng L; Deng N; Tanaka H; Gao B; Liu Z; Sun Z; Bose S; Giuliano AE; Cui X
    Oncogene; 2016 Oct; 35(41):5400-5411. PubMed ID: 27041579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells.
    Zhang X; Zhang B; Zhang P; Lian L; Li L; Qiu Z; Qian K; Chen A; Liu Q; Jiang Y; Cui J; Qi B
    PLoS One; 2019; 14(5):e0217181. PubMed ID: 31120927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes.
    Wang J; Duan Z; Nugent Z; Zou JX; Borowsky AD; Zhang Y; Tepper CG; Li JJ; Fiehn O; Xu J; Kung HJ; Murphy LC; Chen HW
    Cancer Lett; 2016 Aug; 378(2):69-79. PubMed ID: 27164560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells.
    Lin JH; Tu SH; Chen LC; Huang CC; Chang HL; Cheng TC; Chang HW; Wu CH; Wu HC; Ho YS
    Breast Cancer Res Treat; 2018 Nov; 172(1):45-59. PubMed ID: 30054830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.
    Gou X; Anurag M; Lei JT; Kim BJ; Singh P; Seker S; Fandino D; Han A; Rehman S; Hu J; Korchina V; Doddapaneni H; Dobrolecki LE; Mitsiades N; Lewis MT; Welm AL; Li S; Lee AV; Robinson DR; Foulds CE; Ellis MJ
    Cancer Res; 2021 Dec; 81(24):6259-6272. PubMed ID: 34711608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
    Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-33 facilitates endocrine resistance of breast cancer by inducing cancer stem cell properties.
    Hu H; Sun J; Wang C; Bu X; Liu X; Mao Y; Wang H
    Biochem Biophys Res Commun; 2017 Apr; 485(3):643-650. PubMed ID: 28216163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers.
    Parra-Palau JL; Pedersen K; Peg V; Scaltriti M; Angelini PD; Escorihuela M; Mancilla S; Sánchez Pla A; Ramón Y Cajal S; Baselga J; Arribas J
    Cancer Res; 2010 Nov; 70(21):8537-46. PubMed ID: 20978202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance.
    Bekele RT; Venkatraman G; Liu RZ; Tang X; Mi S; Benesch MG; Mackey JR; Godbout R; Curtis JM; McMullen TP; Brindley DN
    Sci Rep; 2016 Feb; 6():21164. PubMed ID: 26883574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GATA3 cooperates with PARP1 to regulate CCND1 transcription through modulating histone H1 incorporation.
    Shan L; Li X; Liu L; Ding X; Wang Q; Zheng Y; Duan Y; Xuan C; Wang Y; Yang F; Shang Y; Shi L
    Oncogene; 2014 Jun; 33(24):3205-16. PubMed ID: 23851505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-484 suppresses endocrine therapy-resistant cells by inhibiting KLF4-induced cancer stem cells in estrogen receptor-positive cancers.
    Wei Y; Li H; Qu Q
    Breast Cancer; 2021 Jan; 28(1):175-186. PubMed ID: 32865695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 14-3-3τ drives estrogen receptor loss via ERα36 induction and GATA3 inhibition in breast cancer.
    Garan LAW; Xiao Y; Lin WC
    Proc Natl Acad Sci U S A; 2022 Oct; 119(43):e2209211119. PubMed ID: 36252018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of tamoxifen resistance and lipid reprogramming in breast cancer.
    Hultsch S; Kankainen M; Paavolainen L; Kovanen RM; Ikonen E; Kangaspeska S; Pietiäinen V; Kallioniemi O
    BMC Cancer; 2018 Aug; 18(1):850. PubMed ID: 30143015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of drug-screening assay for recurrent metastatic hormone receptor-positive, human epidermal receptor 2-negative breast cancer using conditionally reprogrammed cells.
    Mimoto R; Yogosawa S; Saijo H; Fushimi A; Nogi H; Asakura T; Yoshida K; Takeyama H
    Sci Rep; 2019 Sep; 9(1):13405. PubMed ID: 31527634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
    Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
    Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo.
    Schiff R; Reddy P; Ahotupa M; Coronado-Heinsohn E; Grim M; Hilsenbeck SG; Lawrence R; Deneke S; Herrera R; Chamness GC; Fuqua SA; Brown PH; Osborne CK
    J Natl Cancer Inst; 2000 Dec; 92(23):1926-34. PubMed ID: 11106684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.